FDA's July 2026 approval of at-home subcutaneous lecanemab initiation eliminates the 18-month IV requirement, reshaping CNS ...
Mechanical thrombectomy for STEMI with large thrombus burden reduced infarct size by 26% in the NATURE trial, meeting its ...
Cumberland Pharmaceuticals seeks FDA action on ifetroban DMD data from an ongoing extension study, positioning the drug for ...
Dubai Health's rapid whole-genome sequencing rollout for critically ill children delivers diagnostic yields that dwarf ...
AusperBio closes $120M Series C for AHB-137 Hepatitis B program showing 70% functional cure rate in Phase 2 trial data.
MBX Biosciences has dosed the first patient in the Phase 3 canvuparatide trial for hypoparathyroidism, a 160-patient pivotal ...
How Ocular engineered a retinal drug program backward from approval, and what that means for every sponsor still designing ...
Genentech partners with DualityBio on next-generation ADC payloads designed to overcome topoisomerase inhibitor resistance in ...
AbbVie seeks EMA approval for SKYRIZI subcutaneous induction in Crohn's disease following Phase 3 AFFIRM trial success.
Three Phase III wins in a single August, across three distinct tumor types, is not a pipeline story anymore — it is a clinical infrastructure story. Akeso’s ivonescimab, a PD-1/VEGF bispecific ...
A sponsor's mid-study clinical system migration lands on sites first: reconciliation work, documentation risk, and monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results